SEC Filing Summary for Axsome Therapeutics, Inc.

On June 8, 2026, Roger Jeffs, a director at Axsome Therapeutics, Inc., acquired 1,429 shares of Common Stock. This acquisition was part of the vesting of 1,429 Restricted Stock Units (RSUs) that were granted on June 6, 2025. The RSUs vested upon the one-year anniversary of their grant date, converting into common stock on a one-for-one basis. Following this transaction, Mr. Jeffs directly owns 58,939 shares of Common Stock. The reported transactions are Form 4 filings, indicating changes in beneficial ownership by insiders.